Status:
UNKNOWN
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
Lead Sponsor:
University of Cologne
Conditions:
Macular Degeneration
Eligibility:
All Genders
60+ years
Phase:
PHASE4
Brief Summary
To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re na...
Eligibility Criteria
Inclusion
- active subfoveal CNV related to exudative age-related macular degeneration (all subforms)
- age \> 60 years
- visual acuity \> 20/400
- no previous treatment for AMD
Exclusion
- any previous AMD therapy
- other CNV types (myopic, parapapillary)
- contraindication for ranibizumab treatment
- prior study participation for AMD
- pregnancy / premenopausal women
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT01213667
Start Date
January 1 2010
End Date
December 1 2017
Last Update
October 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Center of Ophthalmology
Cologne, North Rhine-Westphalia, Germany, 50924